The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gee, G. W., & Bauder, J. W. (1986) · SSSA Book Series · doi:10.2136/sssabookser5.1.2ed.c15 · Cited by 8,807
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Self-citationImmunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Russell Middaugh, C., Winter, G., Fan, Y.-X., Kirshner, S., Verthelyi, D., Kozlowski, S., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 595
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H.-C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21328 · Cited by 397
Self-citationFactors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Braun, A., Kwee, L., Labow, M. A., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 298
Is any measurement method optimal for all aggregate sizes and types?
Philo, J. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080365 · Cited by 245
A critical review of methods for size characterization of non-particulate protein aggregates
Philo, J. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488815 · Cited by 196
Cited by
Microneedle technologies for (trans)dermal drug and vaccine delivery
van der Maaden, K., Jiskoot, W., & Bouwstra, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.042 · Cited by 651
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3746 · Cited by 529
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Self-citationTherapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Self-citationClassification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Self-citationJoubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.330902 · Cited by 268
Self-citationImmunogenicity of protein aggregates—Concerns and realities
Wang, W., Singh, S. K., Li, N., Toler, M. R., King, K. R., & Nema, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.040 · Cited by 266
Self-citationStructure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Protein Aggregation and Particle Formation in Prefilled Glass Syringes
Gerhardt, A., Mcgraw, N. R., Schwartz, D. K., Bee, J. S., Carpenter, J. F., & Randolph, T. W. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23973 · Cited by 197
Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins
Krayukhina, E., Tsumoto, K., Uchiyama, S., & Fukui, K. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24184 · Cited by 158
Ha, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74
In vitro models for immunogenicity prediction of therapeutic proteins
Groell, F., Jordan, O., & Borchard, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.008 · Cited by 53
Uchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49
In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice
Filipe, V., Que, I., Carpenter, J. F., Löwik, C., & Jiskoot, W. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1154-9 · Cited by 39
Improving Biopharmaceutical Safety Through Verification‐Based Quality Control
Yu, Y. B., Taraban, M. B., Wang, W., & Briggs, K. T. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.08.010 · Cited by 23
Metadata
- Authors
- Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., Narhi, L., Nesta, D. P., & Spitznagel, T.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 99
- Issue
- 8
- Pages
- 3302-3321
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2122748934
- Cited by
- 334
- References
- 22
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.